FR09C0062I2 - Anticorps de la il-1 beta humaine - Google Patents

Anticorps de la il-1 beta humaine

Info

Publication number: FR09C0062I2
Authority: FR; France
Prior art keywords: human; beta antibodies; antibodies; beta
Prior art date: 2000-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR09C0062C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2009-12-03

Publication date

2010-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0062(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-03 Application filed by Novartis AG filed Critical Novartis AG

2010-08-01 Publication of FR09C0062I1 publication Critical patent/FR09C0062I1/fr

2010-12-31 Application granted granted Critical

2010-12-31 Publication of FR09C0062I2 publication Critical patent/FR09C0062I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)

FR09C0062C 2000-08-22 2009-12-03 Anticorps de la il-1 beta humaine Active FR09C0062I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0020685.4A GB0020685D0 (en)	2000-08-22	2000-08-22	Organic compounds
PCT/EP2001/009588 WO2002016436A2 (fr)	2000-08-22	2001-08-20	ANTICORPS DE LA IL-1β HUMAINE

Publications (2)

Publication Number	Publication Date
FR09C0062I1 FR09C0062I1 (fr)	2010-08-01
FR09C0062I2 true FR09C0062I2 (fr)	2010-12-31

Family

ID=9898090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR09C0062C Active FR09C0062I2 (fr)	2000-08-22	2009-12-03	Anticorps de la il-1 beta humaine

Country Status (37)

Country	Link
US (3)	US7446175B2 (fr)
EP (1)	EP1313769B2 (fr)
JP (2)	JP4271936B2 (fr)
KR (2)	KR20080056316A (fr)
CN (1)	CN100547003C (fr)
AR (1)	AR035581A1 (fr)
AT (1)	ATE396206T1 (fr)
AU (2)	AU9549001A (fr)
BE (1)	BE2009C057I2 (fr)
BR (1)	BR0113420A (fr)
CA (1)	CA2420231C (fr)
CY (2)	CY1108779T1 (fr)
CZ (1)	CZ304470B6 (fr)
DE (2)	DE122009000078I1 (fr)
DK (1)	DK1313769T4 (fr)
EC (1)	ECSP034490A (fr)
ES (1)	ES2305110T5 (fr)
FR (1)	FR09C0062I2 (fr)
GB (1)	GB0020685D0 (fr)
HK (1)	HK1061403A1 (fr)
HU (2)	HU228159B1 (fr)
IL (2)	IL154465A0 (fr)
LU (1)	LU91624I2 (fr)
MX (1)	MXPA03001590A (fr)
MY (1)	MY130248A (fr)
NL (1)	NL300427I1 (fr)
NO (3)	NO332609B1 (fr)
NZ (2)	NZ534269A (fr)
PE (1)	PE20020319A1 (fr)
PL (1)	PL212480B1 (fr)
PT (1)	PT1313769E (fr)
RU (1)	RU2286351C2 (fr)
SI (1)	SI1313769T2 (fr)
SK (1)	SK288089B6 (fr)
TW (1)	TWI321568B (fr)
WO (1)	WO2002016436A2 (fr)
ZA (1)	ZA200301275B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1339426A4 (fr) *	2000-11-08	2004-06-30	Human Genome Sciences Inc	Anticorps a liaison immunospecifique avec les recepteurs "trail"
CA2824167C (fr) *	2002-09-06	2018-09-25	Amgen Inc.	Anticorps monoclonal therapeutique anti-il-1r1 humain
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
CA2509136C (fr) *	2003-01-24	2013-10-29	Applied Molecular Evolution, Inc.	Antagonistes de l'il-1 beta humaine
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
US20040224893A1 (en) *	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) *	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
AU2005216298B2 (en)	2004-02-26	2010-09-02	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
US7566772B2 (en) *	2005-01-26	2009-07-28	Amgen Fremont Inc.	Antibodies against interleukin-1β
AU2012213934B9 (en) *	2005-01-26	2013-07-25	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
GB0509512D0 (en) *	2005-05-10	2005-06-15	Novartis Ag	Organic compounds
HUE029021T2 (en)	2005-06-21	2017-02-28	Xoma (Us) Llc	IL-1beta-binding antibodies and fragments thereof
WO2007042524A2 (fr) *	2005-10-14	2007-04-19	Novo Nordisk A/S	Traitement du diabete a l'aide d'inhibiteurs de l'il-1
DK2848258T3 (en) *	2005-10-26	2018-03-19	Novartis Ag	Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
US20100047204A1 (en)	2006-04-14	2010-02-25	Dana Sue Yoo	Use of organic compounds
MX2009006709A (es)	2006-12-20	2009-07-02	Xoma Technology Ltd	Tratamiento de enfermedades relacionadas con il-1beta.
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP1997832A1 (fr) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
US8282922B2 (en) *	2007-05-29	2012-10-09	Novartis Ag	Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
PT2391650E (pt)	2007-12-20	2015-01-14	Xoma Us Llc	Métodos para o tratamento de gota
WO2009134776A2 (fr)	2008-04-29	2009-11-05	Abbott Laboratories	Immunoglobulines à double domaine variable et utilisations
EP2297209A4 (fr)	2008-06-03	2012-08-01	Abbott Lab	Immunoglobulines à deux domaines variables et leurs utilisations
SG191625A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US20110189172A1 (en) *	2008-06-06	2011-08-04	Xoma Technology, Ltd.	Methods for the treatment of rheumatoid arthritis
MX2010014574A (es)	2008-07-08	2011-04-27	Abbott Lab	Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CA2735939A1 (fr)	2008-09-05	2010-03-11	Xoma Technology Ltd.	Procedes pour ameliorer la fonction des cellules beta
MX2011004199A (es) *	2008-10-20	2011-05-24	Abbott Lab	Anticuerpos que unen a il-18 y metodos para purificar los mismos.
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
EP2196476A1 (fr) *	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
EP2427209A1 (fr) *	2009-05-06	2012-03-14	Novartis AG	Thérapie par combinaison d'anticorps anti-il1-
US8389474B1 (en) *	2009-07-14	2013-03-05	Alan Anson Wanderer	Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
CA2772628A1 (fr) *	2009-09-01	2011-03-10	Abbott Laboratories	Immunoglobulines a double domaine variable et leurs utilisations
AU2010306677B2 (en) *	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
KR101860175B1 (ko)	2009-10-26	2018-05-21	에프. 호프만-라 로슈 아게	글리코실화된 면역글로불린의 제조 방법
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2566520A4 (fr)	2010-05-07	2014-02-12	Xoma Us Llc	Méthodes de traitement d'affections associées à l'il-1
AU2011285852B2 (en)	2010-08-03	2014-12-11	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
BR112013004581A2 (pt)	2010-08-26	2017-06-27	Abbvie Inc	imunoglobulinas de domínio variável dual e seus usos
US20140308294A1 (en)	2011-04-15	2014-10-16	Merck Patent Gmbh	Anti-IL-1R1 Inhibitors For Use in Cancer
WO2013007763A1 (fr)	2011-07-12	2013-01-17	Universität Zürich	Modulateurs de la voie d'il-1β de l'inflammasome nlrp3 destiné à la prévention ou au traitement de l'acné
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
US9683038B2 (en)	2011-09-30	2017-06-20	Novartis Ag	Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
WO2013082282A1 (fr)	2011-12-02	2013-06-06	lNOVARTIS AG	Thérapie prophylactique à base d'anticorps anti-il-1bêta (interleukine-1bêta) pour prévenir des complications conduisant à une vaso-occlusion dans une drépanocytose
AU2012352168C1 (en) *	2011-12-14	2018-01-25	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
EP2791171A1 (fr)	2011-12-16	2014-10-22	Synthon Biopharmaceuticals B.V.	Expression d'anticorps iga sécrétoires chez la lentille d'eau
EP2794657B1 (fr)	2011-12-19	2017-10-11	Xoma (Us) Llc	Méthodes de traitement de l'acné
WO2013102042A2 (fr)	2011-12-30	2013-07-04	Abbvie Inc.	Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
HUE049860T2 (hu) *	2012-02-13	2020-11-30	Agency Science Tech & Res	IL-ß-t neutralizáló, humán monoklonális antitestek
CN103588878A (zh) *	2012-08-15	2014-02-19	江苏泰康生物医药有限公司	一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
KR20210111353A (ko)	2012-11-01	2021-09-10	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
BR112015009892B1 (pt)	2012-11-05	2022-12-27	Delenex Therapeutics Ag	Anticorpo contra il-1 beta, seu método de produção e seu uso, sequência isolada de ácido nucleico, vetor, composição cosmética, de diagnóstico ou farmacêutica, e kit
US10000565B2 (en)	2012-11-16	2018-06-19	Novartis Ag	Use of IL-1 β binding antibodies for treating peripheral arterial disease
EP4001307A1 (fr)	2012-12-17	2022-05-25	Cell Medica Inc.	Anticorps dirigés contre il-1 béta
CN104995303A (zh)	2012-12-18	2015-10-21	诺华股份有限公司	利用结合乙酰透明质酸的肽标签的组合物和方法
WO2014144280A2 (fr)	2013-03-15	2014-09-18	Abbvie Inc.	Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
WO2015083120A1 (fr)	2013-12-04	2015-06-11	Novartis Ag	Utilisation d'anticorps de liaison à il-1β
WO2015198243A2 (fr)	2014-06-25	2015-12-30	Novartis Ag	Compositions et procédés pour protéines à action longue
WO2015198240A2 (fr)	2014-06-25	2015-12-30	Novartis Ag	Compositions et procédés permettant d'obtenir des protéines à action prolongée
WO2016008851A1 (fr) *	2014-07-14	2016-01-21	Boehringer Ingelheim International Gmbh	Anticorps anti-il-1b
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr)	2014-10-14	2016-04-21	Dana Farber Cancer Inst Inc	Molécules d'anticorps de pd-l1 et leurs utilisations
CN107001456A (zh)	2014-11-10	2017-08-01	豪夫迈·罗氏有限公司	抗ang2 抗体及使用方法
MX2017005977A (es)	2014-11-10	2017-06-29	Hoffmann La Roche	Anticuerpos biespecificos y metodos de uso en oftalmologia.
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
AU2016272900A1 (en)	2015-06-04	2017-12-07	Novartis Ag	Use of IL-1 beta binding antibodies to treat peripheral arterial disease
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3328418A1 (fr)	2015-07-29	2018-06-06	Novartis AG	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017106656A1 (fr)	2015-12-17	2017-06-22	Novartis Ag	Molécules d'anticorps anti-pd-1 et leurs utilisations
US11377656B2 (en)	2016-03-10	2022-07-05	Novartis Ag	Chemically modified messenger RNA's
US20210292404A1 (en)	2016-07-21	2021-09-23	Novartis Ag	Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
WO2018106931A1 (fr)	2016-12-07	2018-06-14	Progenity Inc.	Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
US20200315540A1 (en)	2016-12-14	2020-10-08	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja)	2017-06-22	2020-08-20	ノバルティスアーゲー	がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
EP3655961A4 (fr) *	2017-07-17	2021-09-01	Massachusetts Institute of Technology	Atlas de cellules de tissus barrières sains et malades
WO2019038740A1 (fr)	2017-08-25	2019-02-28	Novartis Ag	Utilisation de canakinumab
BR112020004903A2 (pt) *	2017-09-13	2020-09-15	Novartis Ag	uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
MX2020004756A (es)	2017-11-16	2020-08-20	Novartis Ag	Terapias de combinacion.
EP3790576A1 (fr) *	2018-05-09	2021-03-17	Novartis Ag	Utilisation de canakinumab
EP3802611A2 (fr)	2018-06-01	2021-04-14	Novartis AG	Molécules de liaison dirigées contre bcma et leurs utilisations
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) *	2018-07-25	2020-01-29	Robert Wotherspoon Hugh	IL-1ß binding antibody
CN110818793A (zh) *	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons
US11976115B2 (en) *	2018-11-07	2024-05-07	Zeda Biopharmaceuticals, Inc.	Antibody binding to human IL-1β, preparation method therefor and use thereof
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
CN113271945A (zh)	2018-12-20	2021-08-17	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
EP3897613A1 (fr)	2018-12-21	2021-10-27	Novartis AG	Utilisation d'anticorps de liaison à il-1bêta
GB201901187D0 (en)	2019-01-29	2019-03-20	Autolus Ltd	Treatment of neurotoxicity and/or cytokine release syndrome
AU2020222346B2 (en)	2019-02-15	2021-12-09	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (fr)	2019-02-15	2020-08-20	Novartis Ag	Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
EP4073115A1 (fr)	2019-12-09	2022-10-19	Novartis AG	Anticorps anti-interleukine 1 bêta pour le traitement de la drépanocytose
WO2021119482A1 (fr)	2019-12-13	2021-06-17	Progenity, Inc.	Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
TW202135858A (zh)	2019-12-20	2021-10-01	瑞士商諾華公司	抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
WO2021257539A1 (fr) *	2020-06-16	2021-12-23	Academia Sinica	ANTICORPS CIBLANT L'INTERLEUKIN-1β ET LEURS UTILISATIONS
JP2023531676A (ja)	2020-06-23	2023-07-25	ノバルティスアーゲー	３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022023907A1 (fr)	2020-07-31	2022-02-03	Novartis Ag	Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
CA3199095A1 (fr)	2020-11-06	2022-05-12	Novartis Ag	Molecules de liaison a cd19 et utilisations associees
WO2022167916A1 (fr)	2021-02-03	2022-08-11	Novartis Ag	Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN117355323A (zh)	2021-05-24	2024-01-05	诺华股份有限公司	用于治疗骨关节炎的方法
US20240294626A1 (en)	2021-06-22	2024-09-05	Novartis Ag	Bispecific antibodies for use in treatment of hidradenitis suppurativa

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US534858A (en) *		1895-02-26		Workman s time-recorder
CA1172789A (fr)	1980-09-25	1984-08-14	Hideo Kasahara	POLYMERE RENFERMANT UN POLYAMIDE LIE A UN COPOLYMERE QUI CONTIENT UN IMIDE D'ACIDE CARBOXYLIQUE INSATURE EN .alpha.,.beta.
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4935343A (en) *	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
EP0364778B1 (fr)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Anticorps contre l'interleukine-1 bêta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (fr)	1989-06-07	1990-12-07	Clyde W. Shearman	Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JP3714683B2 (ja) *	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (fr) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en active Active
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs unknown
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Application Discontinuation
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-20 EP EP01976118A patent/EP1313769B2/fr not_active Expired - Lifetime
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/fr active IP Right Grant
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko active IP Right Grant
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 CA CA2420231A patent/CA2420231C/fr not_active Expired - Lifetime
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
2004
- 2004-04-29 HK HK04103018.8A patent/HK1061403A1/xx not_active IP Right Cessation
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
2009
- 2009-11-24 NL NL300427C patent/NL300427I1/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown

Also Published As

Publication number	Publication date
EP1313769A2 (fr)	2003-05-28
NO2012018I1 (no)	2012-12-10
BE2009C057I2 (fr)	2021-01-28
EP1313769B1 (fr)	2008-05-21
NO2012018I2 (no)	2012-11-21
US20090081732A1 (en)	2009-03-26
DK1313769T3 (da)	2008-09-15
BRPI0113420B1 (pt)	2002-02-28
CA2420231A1 (fr)	2002-02-28
CY2009019I1 (el)	2012-01-25
ECSP034490A (es)	2003-03-31
LU91624I2 (fr)	2010-01-25
JP2008295456A (ja)	2008-12-11
CZ304470B6 (cs)	2014-05-21
AU9549001A (en)	2002-03-04
MY130248A (en)	2007-06-29
NL300427I2 (en)	2010-02-01
US7993878B2 (en)	2011-08-09
KR100910789B1 (ko)	2009-08-04
DE60134148D1 (de)	2008-07-03
NL300427I1 (en)	2010-02-01
NO332609B1 (no)	2012-11-19
ES2305110T3 (es)	2008-11-01
DK1313769T4 (da)	2011-12-05
US20110256151A1 (en)	2011-10-20
CY1108779T1 (el)	2012-01-25
NZ534269A (en)	2006-04-28
IL154465A0 (en)	2003-09-17
KR20030034140A (ko)	2003-05-01
DE122009000078I1 (de)	2010-03-25
US7446175B2 (en)	2008-11-04
IL154465A (en)	2010-11-30
MXPA03001590A (es)	2003-06-04
WO2002016436A2 (fr)	2002-02-28
AR035581A1 (es)	2004-06-16
HUP0300806A3 (en)	2005-09-28
ZA200301275B (en)	2004-04-02
SK2132003A3 (en)	2003-10-07
KR20080056316A (ko)	2008-06-20
NO2017052I2 (no)	2018-05-14
WO2002016436A3 (fr)	2002-06-20
CA2420231C (fr)	2011-04-26
BR0113420A (pt)	2003-07-29
HU228159B1 (en)	2013-01-28
CZ2003505A3 (cs)	2003-05-14
CY2009019I2 (el)	2017-07-12
US20040063913A1 (en)	2004-04-01
FR09C0062I1 (fr)	2010-08-01
PE20020319A1 (es)	2002-06-11
PL212480B1 (pl)	2012-10-31
BRPI0113420B8 (fr)	2021-05-25
JP4271936B2 (ja)	2009-06-03
CN100547003C (zh)	2009-10-07
US8273350B2 (en)	2012-09-25
NO20030827D0 (no)	2003-02-21
CN1484652A (zh)	2004-03-24
SI1313769T2 (sl)	2012-01-31
SK288089B6 (sk)	2013-06-03
SI1313769T1 (sl)	2008-10-31
EP1313769B2 (fr)	2011-11-09
PT1313769E (pt)	2008-08-26
NO20030827L (no)	2003-04-14
PL360358A1 (en)	2004-09-06
RU2286351C2 (ru)	2006-10-27
HK1061403A1 (en)	2004-09-17
ES2305110T5 (es)	2012-03-13
HUP0300806A2 (hu)	2003-12-29
LU91624I9 (fr)	2018-11-19
TWI321568B (en)	2010-03-11
NZ524199A (en)	2004-09-24
AU2001295490B2 (en)	2005-06-16
HUS1300015I1 (hu)	2021-05-28
GB0020685D0 (en)	2000-10-11
NO2017052I1 (no)	2017-10-11
ATE396206T1 (de)	2008-06-15
JP2004506448A (ja)	2004-03-04

Publication	Publication Date	Title
FR09C0062I2 (fr)	2010-12-31	Anticorps de la il-1 beta humaine
IS6779A (is)	2003-04-11	Mannlíkt mótefni gegn LT-beta-R
NO20023266D0 (no)	2002-07-05	Antistoffer mot humant IL-1
DE60023971D1 (de)	2005-12-22	Wegwerfunterwäsche
DE60129523D1 (de)	2007-09-06	Wegwerfunterwäsche
DE60137900D1 (de)	2009-04-23	Wegwerfunterwäsche
DE60104769D1 (de)	2004-09-16	Wegwerfunterwäsche
NO20026063L (no)	2003-02-27	Antistoffer mot human MCP-1
DE60021475D1 (de)	2005-09-01	Wegwerfwindel
DE60018509D1 (de)	2005-04-14	Wegwerfwindel
DE60144260D1 (de)	2011-04-28	Wegwerfwindel
DE60118469D1 (de)	2006-05-18	Keramisches tragwerk
DE60125524D1 (de)	2007-02-08	Wegwerfhöschen
DE60109968D1 (de)	2005-05-19	Wegwerfwindel
DE60018495D1 (de)	2005-04-14	Tamponeinführhilfe
DE60018142D1 (de)	2005-03-24	Tamponapplikator
DE60129917D1 (de)	2007-09-27	Wegwerfunterwäsche
DE60029737D1 (de)	2006-09-14	Wegwerfwindel
DE60120890D1 (de)	2006-08-03	Wegwerfwindel
DE60142667D1 (de)	2010-09-09	Wegwerfunterwäsche
DE60232573D1 (de)	2009-07-23	Damenbinde
ATE258035T1 (de)	2004-02-15	Wegwerfartikel für menschliche fäkalien
DE60025251D1 (de)	2006-02-02	Tamponapplikator
DE60014751D1 (de)	2004-11-18	Wegwerfwindel
DE60105927D1 (de)	2004-11-04	Wegwerfwindel